Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer
- 9 January 2019
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 46 (4) , 848-854
Abstract
Immunotherapy aimed at inhibiting the PD-1/PD-L1 immune checkpoint has been approved and used successfully for the treatment of bladder cancer. The identification of markers predictive of response to immune checkpoint inhibitors is critical to advancing the success of this therapy. 18F-FDG PET/CT is a molecular imaging technique that can provide phenotypic information on malignant tumours. It is currently unknown whether there is a relationship between 18F-FDG uptake and expression of PD-1/PD-L1 in bladder cancer. In this study, we investigated whether PD-1/PD-L1 expression is associated with 18F-FDG uptake in bladder cancer, and whether 18F-FDG PET/CT imaging can be used to predict the PD-1/PD-L1 status of bladder cancer.Keywords
This publication has 27 references indexed in Scilit:
- New Strategies in Bladder Cancer: A Second Coming for ImmunotherapyClinical Cancer Research, 2016
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionCell, 2015
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 2014
- Relationship Between 18F-FDG Accumulation and Lactate Dehydrogenase A Expression in Lung AdenocarcinomasJournal of Nuclear Medicine, 2014
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activationJournal of Experimental Medicine, 2014
- Bladder Cancer in 2010: How Far have We Come?CA: A Cancer Journal for Clinicians, 2010
- 18F-FDG Uptake in Lung, Breast, and Colon Cancers: Molecular Biology Correlates and Disease CharacterizationJournal of Nuclear Medicine, 2009
- HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal CarcinomaCancer Cell, 2008
- T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with SurvivalClinical Cancer Research, 2008